ARGX

Name: AlgoThesis
Author: algothesis

ARGENX SE

NasdaqResearch view

Healthcare · Biological Products, (No Diagnostic Substances) · SEC EDGAR FY 2017-12-31

Price history

Interactive · live data via TradingView

🔒 Click to interact · scroll moves the page

Snapshot

SEC EDGAR · FY 2017-12-31

SectorHealthcare

🔒 Market Cap—

🔒 Enterprise Value—

Income€-28.1M

Sales€36.4M

Book/sh€5.54

Cash/sh€3.08

🔒 Dividend Est.—

Dividend TTM

Finviz-ordered snapshot — SEC EDGAR fundamentals live; 🔒 cells need a licensed price feed. Deeper lines (cash flow, balance sheet) below.

Revenue & Earnings — fiscal year

€6.9M

2015

€14.7M

2016

€36.4M

2017

Financials — annual

SEC EDGAR · last 3 FY

EUR	FY2015	FY2016	FY2017
Revenue	€6.9M	€14.7M	€36.4M
Gross Profit	—	—	—
Operating Income	€-15.6M	€-21.4M	€-22.9M
Net Income	€-15.3M	€-21.4M	€-28.1M
Diluted EPS	—	—

Deep dive

Computed from the SEC EDGAR multi-year statements

Operating leverage — margins

GrossOperatingNet

AI Bull vs Bear — ARGX

Every story opens a two-sided AI breakdown — not just a headline.

All stories →

argenx to acquire Forte Biosciences for $2.2 billion in cash

Investing.com · 6d ago

Bull vs Bear →

COMMUNITY · $ARGX0 theses

POST YOUR TAKE →

Related Stocks

Loading peers…

Ask AI about ARGX Build basket with ARGX Screener

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.